October 22nd 2024
The expanded indication of Selarsdi for the treatment of diseases such as psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn disease is expected to support the official launch early next year.
From Potential to Value: Carving a Slice of the CGT ‘PIE'
August 15th 2024The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.
FDA Approves Citius Pharmaceuticals’ Lymphir for Relapsed or Refractory Cutaneous T-Cell Lymphoma
August 9th 2024Lymphir is the first therapy to target the IL-2 receptor in the treatment of relapsed or refractory cutaneous T-cell lymphoma and the first FDA-approved product for Citius Pharmaceuticals.